Loading...
•
Mar 31, 2022
Teladoc Q1 2022 Earnings Report
Teladoc's financial performance was marked by revenue growth, offset by a substantial net loss due to a goodwill impairment charge and revised full-year guidance.
Key Takeaways
Teladoc Health reported a 25% increase in revenue to $565.4 million for Q1 2022. However, the company experienced a significant net loss of $6.67 billion, or $41.58 per share, primarily due to a $6.6 billion non-cash goodwill impairment charge. The full-year guidance for 2022 has been revised to $2.4 - $2.5 billion in revenue, a net loss per share of ($43.50) - ($43.00), and adjusted EBITDA of $240 - $265 million.
Revenue grew by 25% year-over-year, reaching $565.4 million.
Net loss was $6.67 billion, or $41.58 per share, heavily impacted by a non-cash goodwill impairment charge.
Access fees revenue increased by 29% to $491.3 million, while visit fee revenue grew by 12% to $67.9 million.
Full year guidance was revised to reflect dynamics in the D2C mental health and chronic condition markets.
Revenue by Geographic Location
Forward Guidance
For the second quarter of 2022, Teladoc Health expects revenue between $580 and $600 million, and adjusted EBITDA between $39 and $49 million. For the full year 2022, the company anticipates revenue between $2.4 and $2.5 billion, and adjusted EBITDA between $240 and $265 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...